BeyondSpring Inc. (BYSI)

BeyondSpring's stock price has decreased over the past six months. Key events impacting the stock price include the Q3 2025 and Q4 2025 earnings releases, a delay in a significant financing event, a poster presentation at the AACR Annual Meeting 2026 regarding Plinabulin and ADC combination data, and the report of compelling new data for Plinabulin advancing both the anticancer efficacy and safety of ADC drugs.

BeyondSpring, Inc. is a clinical-stage biopharmaceutical company, its revenue is primarily derived from financing activities rather than product sales, therefore, traditional demand seasonality is not applicable. The company's focus remains on advancing its pipeline through clinical trials and seeking regulatory approvals.

BeyondSpring, Inc., founded in 2010, is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for oncology and hematology. Their lead product candidate, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and for the prevention of chemotherapy-induced neutropenia. BeyondSpring also has a pipeline of early-stage immuno-oncology product candidates and a subsidiary, Seed Therapeutics, focusing on a targeted protein degradation molecular glue platform.

BeyondSpring, Inc. is headquartered in Florham Park, New Jersey, United States. The company has a global footprint with a diverse workforce and a commitment to bringing therapies to patients worldwide, and has a strategic partnership with Hengrui for Greater China regarding Plinabulin.

In the past year, BeyondSpring's brand reputation has been positively influenced by scientific and clinical advancements. The company reported compelling new data for Plinabulin, presented at oncology conferences, and published clinical study results in reputable journals. The company emphasizes its commitment to ethical, environmental, and socially responsible practices.

The ownership structure of BeyondSpring (BYSI) stock includes institutional, retail, and individual investors. Approximately 9.34% to 13.07% of the company's stock is owned by Institutional Investors, around 9.80% by Insiders, and approximately 77.13% is held by Public Companies and Individual Investors (retail investors). Major institutional owners include Decheng Capital LLC, Vanguard Group Inc, and BlackRock, Inc.